Enforcement watch

Peptide gray market in numbers: 5 warning letters, AU$120,000, 2.5x dose gaps

Q: Why did the FDA send 5 warning letters on one day?

On August 24, 2026 the FDA issued warning letters to Peptide Partners LLC, Royal Peptides LLC, Peak Performance Peptides, TXP Innovations LLC and NuScience Peptides LLC. All 5 cited PT-141, bremelanotide, as an unapproved new drug. The FDA held that research-use-only labelling does not negate intended human use, and that selling bacteriostatic water alongside supplies the means to inject.

Q: What was in the seized Wolverine Stack?

The Australian TGA seized over AU$120,000 of product from 2 residential premises in New South Wales. The stack combined BPC-157 and TB-500. BPC-157 has zero published human clinical trials. TB-500 has zero. The seller was a previously warned social-media influencer who imported, relabelled and resold the products.

Q: How inaccurate were the Melanotan II doses?

TGA laboratory testing assayed 5 bottles of one product labelled 30 mg per bottle. Measured content ranged from 22 mg to 54 mg. That is a 2.5x spread between the weakest and strongest bottle of the same labelled product. Zero Melanotan II products are registered in Australia or Hong Kong.

Q: Is the approved side any better evidenced?

Yes, by three orders of magnitude. The CagriSema meta-analysis pools 7 RCTs with 8,069 participants. CagriSema beat semaglutide by 7.58 kg and placebo by 13.99 kg. Dulaglutide has a new 80-person randomized trial with an effect size of 1.69 on glycaemic variability. The gray-market peptides named above have zero human trials each.

August 2026 produced the sharpest picture yet of the unapproved peptide market. Regulators seized product, tested it, and sent letters. The numbers tell the story.

5 FDA letters in 1 dayAU$120,000 seized in Australia22 to 54 mg on a 30 mg label

In short

The gray peptide market has no dosing control, no human trials, and rising enforcement. The approved side of the same molecule class ran 7 randomized trials with 8,069 people.

Five FDA warning letters went out on August 24, all citing PT-141 as an unapproved new drug. Australia's TGA seized over AU$120,000 of product including a BPC-157 and TB-500 stack, and its lab found 22 to 54 mg of Melanotan II in bottles labelled 30 mg. In the same month, a meta-analysis of 7 CagriSema trials covering 8,069 participants reported 7.58 kg more weight loss than semaglutide.

5 warning letters, 1 day 0 human trials for BPC-157 8,069 participants, CagriSema

The catch: enforcement targets sellers, not buyers. Nothing in the August actions makes the products safer, purer, or accurately dosed.

Same month, two worlds

8,069 participants versus zero

Two evidence bases updated in the same 4 weeks. One runs through prescription drug development. The other runs through social-media sellers. The gap is the story.

Swipe the chart sideways

Every bar is a measured evidence base. CagriSema pools 7 randomized trials with 8,069 participants[6]. Dulaglutide added an 80-person randomized trial in August alone[7]. GHK-Cu's entire aesthetic RCT base is 54 participants across 2 trials[5]. BPC-157, TB-500, CJC-1295 and ipamorelin have zero published human trials between them[4].

A 2026 network meta-analysis of 58 trials and 24,214 participants ranks CagriSema third for weight loss behind retatrutide and tirzepatide[8]. That is the scale the approved pathway operates at. The gray market has no comparable dataset for anything it sells.

Five letters in one day

On August 24, 2026, the FDA issued warning letters to 5 peptide sellers: Peptide Partners LLC, Royal Peptides LLC, Peak Performance Peptides, TXP Innovations LLC and NuScience Peptides LLC. Every letter cites PT-141, bremelanotide, as an unapproved new drug under sections 201(g)(1), 201(p), 301(d) and 505(a) of the FD&C Act[1].

Two details matter for anyone buying peptides online. First, the sellers argued their products were for research use only and not for human consumption. The FDA rejected that argument: marketing claims covering arousal, desire, libido and mood showed intended human use. Second, the sellers co-marketed bacteriostatic water. The FDA treated that as supplying the means to prepare an injectable for human administration[1].

The pattern to remember: research-use-only label plus injection supplies plus benefit claims equals unapproved new drug in the FDA's reading. Bremelanotide itself is not new. An approved version exists on prescription. The letters target the unapproved sales channel, not the molecule.

The seizure and the assay

Australia's TGA executed warrants on 2 residential premises in New South Wales on August 4 and announced the result on August 17: over AU$120,000 of illicit peptide and steroid product seized. The haul included a combination marketed as a Wolverine Stack, pairing BPC-157 with TB-500, plus retatrutide and CJC-1295[2]. The seller was a previously warned social-media influencer who imported, relabelled and resold the products. Civil penalties reach AU$1.82 million per breach for an individual and AU$18.2 million for a corporation, with up to 7 years imprisonment as the criminal maximum.

Then the laboratory work started. Five bottles of a Melanotan II nasal spray labelled 30 mg per bottle were assayed. Measured content ran from 22 mg to 54 mg[3].

Swipe the chart sideways

Same product, same label, 2.5x spread. The lowest bottle delivered 73% of its label. The highest delivered 180%. Dosing consistency is a manufacturing discipline; unregulated supply chains have none[3].

Zero Melanotan II products are registered in the Australian Register of Therapeutic Goods. Zero are registered in Hong Kong. Consumers were told to stop use and dispose of the product at a pharmacy.

The August 2026 enforcement log

Date	Regulator	Action	Peptides named	Numbers
Aug 17	TGA (Australia)	Seizure, 2 NSW premises, influencer reseller	BPC-157, TB-500, retatrutide, CJC-1295	AU$120,000+ seized; penalties to AU$18.2M per corporate breach[2]
Aug 18	TGA via HK Drug Office	Laboratory assay of seized tanning spray	Melanotan II	22 to 54 mg measured against a 30 mg label, 5 bottles[3]
Aug 24	FDA (USA)	5 warning letters issued the same day	PT-141 (bremelanotide)	5 sellers: unapproved new drug despite research-use-only labels[1]

All three actions were verified against the primary regulator pages.

Evidence check

What the new reviews actually found

Enforcement is one signal. The evidence base is another. Three reviews published in August 2026 sized the human data behind the gray market's bestsellers.

Peptides	Review	What was counted	Bottom line
BPC-157, TB-500, CJC-1295, ipamorelin	Scoping review, Am J Sports Med	67% animal models; human data a handful of uncontrolled studies; effects modest at best	Authors recommend against adjunct use in orthopaedic care[4]
GHK-Cu	Systematic review, Aesthet Surg J	933 records screened, 20 studies, only 2 RCTs, 54 human participants total	Satisfaction P=.04 but wrinkle reduction P=.77 in the key RCT, n=13 analysed[5]
MOTS-c, humanin	Systematic review, Physiol Int	435 records screened, 9 studies, exercise exposure only	No pooled effect size, no dosing data, no interventional human trials[9]

The sports medicine scoping review is the widest lens. It pulled every publication on BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu. Two thirds used preclinical animal models, mostly rats. The human studies that exist are a handful, mostly without robust controls. The authors' own recommendation: do not use these peptides as an adjunct to orthopaedic standard of care[4].

The GHK-Cu review shows how thin even a popular peptide's aesthetic evidence is. Twenty studies made the cut. Eighteen were preclinical or non-randomised. The two RCTs total 54 participants. In the pivotal laser-resurfacing trial with 13 analysed, satisfaction favoured GHK-Cu at P=.04, but wrinkle reduction missed at P=.77[5].

What this means for a buyer

None of the August actions ban peptides as a category. They document what the unapproved channel actually ships: products with no human trials behind them, no quality system around them, and in one tested case a 2.5x dosing spread inside a single product line.

The approved route

GLP-1 class

Trials: 7 RCTs, n=8,069 (CagriSema meta)

Effect: minus 7.58 kg vs semaglutide

Prescription medicines with large randomized programs. GI side effects are the main cost.

Evidence tier ARead the meta-analysis

The gray market

Unapproved injectables

Human trials: 0 for BPC-157, TB-500, CJC-1295, ipamorelin

Dose accuracy: 22 to 54 mg on a 30 mg label

No approval pathway, no quality system, no dosing consistency. Enforcement is accelerating.

Evidence tier FRead the seizure notice

What to check before buying

Three questions

Registered? in the ARTG or FDA drug register

Assayed? a CoA with batch numbers

If a seller markets injection aids next to research-use-only labels, that exact pattern drew 5 FDA warning letters on Aug 24.

Due diligenceRead the testing guide

The approved contrast, in numbers

CagriSema, a cagrilintide and semaglutide co-formulation pending approval decisions, now has a GRADE-assessed meta-analysis: 7 randomized trials, 8,069 participants, weight loss of 7.58 kg more than semaglutide, 9.24 kg more than cagrilintide, and 13.99 kg more than placebo, all at p<0.00001. Serious adverse events did not increase[6].

Dulaglutide added the DIADEMA trial in August: 80 adolescents with thalassaemia-induced diabetes, 24 weeks, 0.75 mg weekly. Glucose variability fell 4.4 points while insulin worsened it, with a between-group effect size of 1.69[7]. Not a longevity result, but a randomized one, published, and reproducible.

That is the comparison that matters. The same 4 weeks produced 8,069-participant meta-analytic evidence for one channel and laboratory-confirmed dose chaos in the other.

Frequently asked questions

Why did the FDA send 5 warning letters on one day?